Literature DB >> 22748604

Discontinuation of statin therapy due to muscular side effects: a survey in real life.

D Rosenbaum1, J Dallongeville, P Sabouret, E Bruckert.   

Abstract

BACKGROUNDS AND AIMS: To assess the burden of statin related muscular symptom in real life. METHODS AND
RESULTS: We conducted a wide survey on 10,409 French subjects. Among these, 2850 (27%) had hypercholesterolemia and 1074 were treated with statins. Muscular symptoms were reported by 104 (10%) statin treated patients and led to discontinuation in 30% of the symptomatic patients. The main prescribed statins were low doses rosuvastatin, atorvastatin and simvastatin. Pains were the most commonly described symptoms (87%) but many patients also reported stiffness (62%), cramps (67%), weakness or a loss of strength during exertion (55%). Pain was localized in 70% but mostly described as affecting several muscular groups. Approximately 38% of patients reported that their symptoms prevented even moderate exertion during everyday activities, while 42% of patients suffered major disruption to their everyday life.
CONCLUSION: Muscular symptoms associated with average dosage statin therapy are more frequent than in clinical trials and have a greater impact on patients' life than usually thought.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dyslipidemia; Muscular symptoms; Real life survey; Side effects; Statins

Mesh:

Substances:

Year:  2012        PMID: 22748604     DOI: 10.1016/j.numecd.2012.04.012

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  31 in total

Review 1.  A comprehensive review and meta-analysis of risk factors for statin-induced myopathy.

Authors:  Khoa A Nguyen; Lang Li; Deshun Lu; Aida Yazdanparast; Lei Wang; Rolf P Kreutz; Elizabeth C Whipple; Titus K Schleyer
Journal:  Eur J Clin Pharmacol       Date:  2018-05-22       Impact factor: 2.953

2.  RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Authors:  Paul J Isackson; Jianxin Wang; Mohammad Zia; Paul Spurgeon; Adrian Levesque; Jonathan Bard; Smitha James; Norma Nowak; Tae Keun Lee; Georgirene D Vladutiu
Journal:  Pharmacogenomics       Date:  2018-10-16       Impact factor: 2.533

Review 3.  Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms-A Good Idea, but….

Authors:  Amanda L Zaleski; Beth A Taylor; Paul D Thompson
Journal:  Adv Nutr       Date:  2018-07-01       Impact factor: 8.701

4.  Influence of Baseline Psychological Health on Muscle Pain During Atorvastatin Treatment.

Authors:  Amanda L Zaleski; Beth A Taylor; Linda S Pescatello; Ellen A Dornelas; Charles Michael White; Paul D Thompson
Journal:  J Cardiovasc Nurs       Date:  2017 Nov/Dec       Impact factor: 2.083

Review 5.  Statin intolerance: diagnosis and remedies.

Authors:  Angela Pirillo; Alberico Luigi Catapano
Journal:  Curr Cardiol Rep       Date:  2015-05       Impact factor: 2.931

6.  Medication Discontinuation in the IMPROVE-IT Trial.

Authors:  Ann Marie Navar; Matthew T Roe; Jennifer A White; Christopher P Cannon; Yuliya Lokhnygina; L Kristin Newby; Robert P Giugliano; Andrew M Tershakovec; Eugene Braunwald; Robert M Califf; Michael A Blazing
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-01

Review 7.  Statins as a preventative therapy for venous thromboembolism.

Authors:  Alex Wallace; Hassan Albadawi; Peter Hoang; Andrew Fleck; Sailendra Naidu; Grace Knuttinen; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 8.  Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women.

Authors:  Flavia Franconi; Ilaria Campesi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

9.  Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils.

Authors:  Chandrasekaran Indumathi; Natarajan Anusha; Kolar Vishwanath Vinod; Satheesh Santhosh; Steven Aibor Dkhar
Journal:  J Clin Diagn Res       Date:  2017-07-01

10.  Blue-Green Algae Inhibit the Development of Atherosclerotic Lesions in Apolipoprotein E Knockout Mice.

Authors:  Chai Siah Ku; Bohkyung Kim; Tho X Pham; Yue Yang; Casey J Wegner; Young-Ki Park; Marcy Balunas; Ji-Young Lee
Journal:  J Med Food       Date:  2015-11-13       Impact factor: 2.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.